Search

1179 Result(s)
Sort by

Living with heart failure

Living with heart failure

Hear Patricia’s story on the impact that heart failure can have on mental health and the importance of finding support networks.
AMR_Action_Fund

AMR_Action_Fund

Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
Partnering with Boehringer Ingelheim

Partnering with Boehringer Ingelheim

Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
Elke

Elke

People with Type 2 diabetes (T2D) have an increased risk of heart disease.
Dan

Dan

People with Type 2 diabetes (T2D) have an increased risk of heart disease
CHMP_opinion_nintedanib_ILD_PF

CHMP_opinion_nintedanib_ILD_PF

Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Boehringer Ingelheim Academy Video 2023

Boehringer Ingelheim Academy Video 2023

Boehringer Ingelheim’s Academy initiative provides networking opportunities, education and facilitates conversations across the innovation community.
ATM-Ranking-2021

ATM-Ranking-2021

Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
Revolutionizing drug development

Revolutionizing drug development

Our scientists are leveraging the "digital twins"-technology to revolutionize biotherapeutic drug development.
Expert Advice from Dr Clare Shaw

Expert Advice from Dr Clare Shaw

Consultant oncology dietitian Dr Clare Shaw shares her advice on some of the most common cancer nutrition misunderstandings.
EC_approval_nintedanib_ILD_PF

EC_approval_nintedanib_ILD_PF

European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF